Main ion channels and receptors associated with visceral hypersensitivity in irritable bowel syndrome

Annals of Gastroenterology

Volumn 27, Issue 3, 2014, Pages 200-206

  Rocha, Heraldo Arcela de Carvalho ^a   Dantas, Bruna Priscilla Vasconcelos ^a   Rolim, Thaísa Leite ^a   Costa, Bagnólia Araújo ^a   de Medeiros, Arnaldo Correia ^a  

^a FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

Author keywords

Ion channels; Irritable bowel syndrome; Visceral hypersensitivity

Indexed keywords

ACID SENSING ION CHANNEL; ADENOSINE TRIPHOSPHATE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CHOLECYSTOKININ RECEPTOR; ION CHANNEL; PROTEINASE ACTIVATED RECEPTOR 2; RECEPTOR PROTEIN; SEROTONIN RECEPTOR; VANILLOID RECEPTOR 1; VOLTAGE GATED CALCIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL;

ABDOMINAL PAIN; DEPOLARIZATION; DISEASE ASSOCIATION; ENTEROPATHY; GENOTYPE; HUMAN; INTESTINE MOTILITY; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; VISCERAL HYPERSENSITIVITY;

EID: 84903477457     PISSN: 11087471     EISSN: 17927463     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-1390.
2. Lembo T, Naliboff B, Munakata J, et al. Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 1999;94:1320-1326.
3. Mearin F, Perelló A, Balboa A. Síndrome del intestino irritable y enfermedad inflamatoria intestinal: alguna conexión? Gastroenterol Hepatol 2009;32:364-372.
4. Alonso C, Santos J. A closer look at mucosal inflammation in irritable bowel syndrome: sex-and-gender-related disparities-quantity, quality, or both? Am J Gastroenterol 2009;104:401-403.
5. Francesconi CF, Damião ADMC, Vieira A, et al. Fisiopatologia. In: Quilici FA. Síndrome do Intestino Irritável: visão integrada ao Roma III. 2 ed. Segmento Farma: São Paulo, 2008. pp. 33-59.
6. Akbar A, Walters JRF, Ghosh S. Review article: visceral hypersensitivity in irritable bowel syndrome: molecular mechanisms and therapeutic agents. Aliment Pharmacol Ther 2009;30:423-435.
7. Christianson JA, Davis BM. The role of visceral afferents in disease. In: Kruger L, Light AR. Translational pain research: from mouse to man. Boca Raton: CRC Press, 2010.
8. Lewin GR, Barde YA. Physiology of the neurotrophins. Annu Rev Neurosci 1996;19:289-317.
9. Cervero F, Janig W. Visceral nociceptors: a new world order? Trends Neurosci 1992;15:374-378.
10. Mayer EA, Gebhart GT. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994;107:271-293.
11. Shinoda M, Feng B, Gebhart GF. Peripheral and central P2X3 receptor contributions to colon mechanosensitivity and hypersensitivity in the mouse. Gastroenterology 2009;137:2096-2104.
12. Xu GY, Shenoy M, Winston JH, et al. P2X receptor-mediated visceral hyper algesia in a rat model of chronic visceral hypersensitivity. Gut 2008;57:1230-1237.
13. Keating C, Pelegrin P, Martinez CM, et al. P2X7 receptor-dependent intestinal afferent hypersensitivity in a mouse model of post infectious irritable bowel syndrome. J Immunol 2011;187:1467-1474.
14. Wood JN. Recent advances in understanding molecular mechanisms of primary afferent activation. Gut 2004;53:ii9-ii12.
15. Fein A. Nociceptores-As células que sentem dor. Petrov P, Francischi JN, Ferreira SH, et al. tradutores. Ribeirão Preto-SP: Dor On Line 106 p. Disponivel em: http://www.dol.inf.br/nociceptores, 2011.
16. Catterall WA. Cellular and molecular biology of voltage-gated sodium channels. Physiol Rev 1992;72:S15-S48.
17. Akopian AN, Souslova V, England S, et al. The tetrodotoxin-resistant sodium channel SNS has a specialized function in pain pathways. Nat Neurosci 1999;2:541-548.
18. Verne GN, Sen A, Price DD. Intrarectal lidocaine is an effective treatment for abdominal pain associated with diarrhea-predominant irritable bowel syndrome. J Pain 2005;6:493-496.
19. Yangou Y, Facer P, Chessell IP, et al. Voltage-gated ion channel Nav1.7innervation in patients with idiopathic rectal hypersensitivity and paroxysmal extreme pain disorder (familial rectal pain). Neurosci Lett 2007;427:77-82.
20. Cribbs LL. T-type Ca2+ channels in vascular smooth muscle: Multiple functions. Cell Calcium 2006;40:221-230.
21. Perez-Reyes E. Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev 2003;83:117-161.
22. Yu FH, Catterall WA. The VGL-chanome: a protein superfamily specialized for electrical signaling and ionic homeostasis. Sci STKE 2004;253:15.
23. Sonkusare S, Palade PT, Marsh JD, et al. Vascular calcium channel and high blood pressure: Pathophysiology and therapeutic implications. Vascul Pharmacol 2006;44:131-142.
24. Zamponi GW, Lory P, Perez-Reyes E. Role of voltage-gated calcium channels in epilepsy. Pflugers Arch 2010;460:395-403.
25. Marger F, Gelot A, Alloui A, et al. T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome Proc Natl Acad Sci USA 2011;108:11268-11273.
26. Bolton TB, Prestwich SA, Zholos AV, et al. Excitation-contraction coupling in gastrointestinal and other smooth muscles. Annu Rev Physiol 1999;61:85-115.
27. Liu X, Rusch NJ, Striessnig J, Sarna SK. Down-regulation of L-type calcium channels in inflamed circularsmooth muscle cells of the canine colon. Gastroenterology 2001;120:480-489.
28. Choudhury BK, Shi XZ, Sarna SK. Gene plasticity in colonic circular smooth muscle cells underlies motility dysfunction in a model of postinfective IBS. Am J Physiol Gastrointest Liver Physiol 2009;296:632-642.
29. Wegener JW, Schulla V, Koller A, et al. Control of intestinal motility by the Ca(v)1.2 L-type calcium channel in mice. FASEB J 2006;20:1260-1262.
30. Zhang M, Leung EP, Huang Y, et al. Increased colonic motility in a rat model of irritable bowel syndrome is associated with up-regulation of L-type calcium channels in colonic smooth muscle cells. Neurogastroenterol Motil 2006;22:162-170.
31. Kirschstein T, Rehberg M, Bajorat R, et al. High K+-induced contraction requires depolarization-induced Ca2+ release from internal stores in rat gut smooth muscle. Acta Pharmacol Sin 2009;30:1123-1131.
32. Page AJ, Brierley SM, Martin CM, et al. Acid sensing ion channels 2 and 3 are required for inhibition of visceral nociceptors by benzamil. Pain 2007;133:150-160.
33. Jones RC, Otsuka E, Wagstrom E, et al. Short-term sensitization of colon mechanoreceptors is associated with long-term hypersensitivity to colon distention in the mouse. Gastroenterology 2007;133:184-194.
34. Nystedt S, Larsson AK, Aberg H, et al. The mouse proteinase activated receptor-2 cDNA and gene. Molecular cloning and functional expression. J Biol Chem 1995;270:5950-5955.
35. Bueno L. Protease activated receptor 2: a new target for IBS treatment. Eur Rev Med Pharmacol Sci 2008;12(Suppl 1):95-102.
36. Macfarlane SR, Seatter MJ, Kanke T, et al. Proteinase-activated receptors. Pharmacol Rev 2001;53:245-282.
37. Kong WK, McConalogue LM, Khitin MD, et al. Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc Natl Acad Sci USA 1997;94:8884-8889.
38. Vergnolle N, Wallace JL, Bunnett NW, et al. Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 2001;22:146-152.
39. Vergnolle N, Cellars L, Mencarelli A, et al. A role for proteinaseactivated receptor-1 in inflammatory bowel diseases. J Clin Invest 2004;114:1444-1456.
40. Cenac N, Andrews CN, Holzhausen M, et al. Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007;117:636-647.
41. Greenwood-van MB. Importance of 5-hydroxytryptamine receptors on intestinal afferents in the regulation of visceral sensitivity. Neurogastroenterol Motil 2007;19(Suppl 2):13-18.
42. Gershon MD. Review article: serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 2004;20:3-14.
43. Gershon MD. Nerves, reflexes, and the enteric nervous system: pathogenesis of the irritable bowel syndrome. J Clin Gastroenterol 2005;39:S184-S193.
44. Gershon MD, Tack J. The serotonin signalling system: From basic understanding to drug development for functional GI disorders. Gastroenterology 2007;132:397-414.
45. Bueno L, Fioramonti J. Visceral perception: inflammatory and non-inflammatory mediators. Gut 2002;51(Suppl 1):i19-i23.
46. Azpiroz F, Bouin M, Camilleri M, et al. Mechanisms of hypersensitivityin IBS and functional disorders. Neurogastroenterol Motil 2007;19(Suppl 1):62-88.
47. Delgado-Aros S, Camilleri M. Visceral hypersensitivity. J Clin Gastroenterol 2005;39(Suppl 5):S194-S203.
48. Holzer P. Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. Eur J Pharmacol 2001;429:177-193.
49. Camilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001;15:277-289.
50. Steadman CJ, Talley NJ, Phillips SF, et al. Selective 5-hydroxytryptamine type 3 receptor antagonism with on dansetron as treatment for diarrhea predominant irritable bowel syndrome: a pilot study. Mayo Clin Proc 1992;67:732-738.
51. Tabas G, Beaves M, Wang J, et al. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004;99:914-920.
52. Vahedi H, Merat S, Rashidioon A, et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized controlled study. Aliment Pharmacol Ther 2005;22:381-385.
53. Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006;55:1095-1103.
54. Storr MA, Yüce B, Andrews CN, et al. The role of the endocannabinoid system in the pathophysiology and treatment of irritable bowel syndrome. Neurogastroenterol Motil 2008;20:857-868.
55. Pertwee RG. Cannabinoids and the gastrointestinal tract. Gut 2001;48:859-867.
56. Duncan M, Mouihate A, Macki, K, et al. Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liv Physiol 2008;295:G78-G87.
57. Landi M, Croci T, Rinaldi-Carmona M, et al. Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB1 receptors. Eur J Pharmacol 2002;450:77-83.
58. Rousseaux C, Thuru X, Gelot A, et al. Lactobacillus acidophilus Annals of Gastroenterology 27 Visceral hypersensitivity in irritable bowel syndrome 7 modulates intestinal pain and induces opioid and cannabinoid receptors. Nat Med 2007;13:35-37.
59. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-551.
60. Park JM, Choi MG, Cho YK. Cannabinoid receptor 1 gene polymorphism and irritable bowel syndrome in the Korean population: a hypothesis-generating study. J Clin Gastroenterol 2011;45:45-49.
61. Clapham DE. TRP channels as cellular sensor. Nature 2003;426:517-524.
62. Phelps CB, Gaudet R. The role of the N terminus and transmembrane domain of TRPM8 in channel localization and tetramerization. J Biol Chem 2007;282:36474-36480.
63. Montell C. The TRP superfamily of cation channels. Science STKE, re3, 2005.
64. Venkatachalam K, Montell C. TRP channels. Ann Rev Biochem 2007;76:387-417.
65. Montell C, Birnbaumer L, Flockerzi V. The TRP channels, a remarkably functional family. Cell 2002;108:595-598.
66. Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816-824.
67. Matsumoto K, Hosoyaa T, Tashimaa K, et al. Distribution of transient receptor potential vanilloid 1 channel-expressing nerve fibers in mouse rectal and colonic enteric nervous system: relationship to peptidergic and nitrergic neurons. Neuroscience 2011;172:518-534.
68. Chan CLH, Facer P, Davis JB, et al. Sensory fibres expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 2003;361:385-391.
69. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702.
70. Hughes PA, Brierley SM, Martin CM, et al. TRPV1-expressing sensory fibers and IBS: links with immune function. Gut 2009;58:465-466.
71. Crawley JN, Corwin RL. Biological actions of cholecystokinin. Peptides 1994;15:731-755.
72. Miyasaka K, Funakoshi A. Cholecystokinin and cholecystokinin receptors. J Gastroenterol 2003;38:1-13.
73. Noble F, Wank SA, Crawley JN, et al. International Union of Pharmacology: XXI. Structure, distribution, and functions of cholecystokinin receptors. Pharmacol Rev 1999;51:745-781.
74. Sternini C, Wong H, Pham T, et al. Expression of cholecystokinin in A receptors in neurons innervating the rat stomach and intestine. Gastroenterology 1999;117:1136-1146.
75. Varga G, Balint A, Burghardt B, et al. Involvement of endogenous CCK and CCK1 receptors in colonic motor function. Br J Pharmacol 2004;141:1275-1284.
76. Deschenes RJ, Lorenz LJ, Haun RS, et al. Cloning and sequence analysis of ac DNA encoding rat preprocholecystokinin. Proc Natl Acad Sci USA 1984;81:726-730.
77. Rehfeld JF, Hansen HF. Characterization of preprocholecystokinin products in the porcine cerebral cortex. Evidence of different processing pathways. J Biol Chem 1986;261:5832-5840.
78. Wank SA. G protein-coupled receptors in gastrointestinal physiology. I. CCK receptors: an exemplary family. Am J Physiol 1998;274:G607-G613.
79. Archer E, Maigret B, Escrieut C, et al. Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors? Trends Pharmacol Sci 2003;24:36-40.
80. Roberts-Thomson IC, Fettman MJ, Jonsson JR, et al. Responses to cholecystokinin in octapeptide in patients with functional abdominal pain syndromes. J Gastroenterol Hepatol 1992;7:293-297.
81. Sjolund K, Ekman R, Lindgren S, et al. Disturbed motilin and cholecystokinin release in the irritable bowel syndrome. Scand J Gastroenterol 1996;31:1110-1114.
82. Chey WY, Jin HO, Lee MH, et al. Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001;96:1499-1506.
83. Zhang H, Yan Y, Shi R, et al. Correlation of gut hormones with irritable bowel syndrome. Digestion 2008;78:72-76.
84. D'Amato M, Whorwell P, Thompson DG. The efficacy and safety of the CCKA receptor antagonist dexloxiglumide in IBS. Gut 1999;45:A258.